Blood samples may unlock secrets of cancer drug resistance
NCT ID NCT05272423
First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 3 times
Summary
This study collects blood samples from up to 500 adults in the US with KRAS G12C-positive cancer whose disease has progressed after treatment with a KRAS inhibitor. Researchers will analyze the samples to identify genetic changes that cause resistance. The goal is to compare resistance patterns between different drugs and cancer types, which may guide future treatment strategies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal why some cancers become resistant to KRAS inhibitors, pointing toward better combination treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It collects data only, so it won't directly help participants. Results may not lead to new therapies quickly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS P.G12C are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- New pill targets Hard-to-Treat lung cancer in patients who Can't have standard therapy
- New targeted pill shows promise for Hard-to-Treat pancreatic cancer
- New hope for elderly lung cancer patients: targeted pill shows promise
- New pill targets Hard-to-Treat cancer mutation